Related Experiment Videos
Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery
D. Hamid1, B. Duclos, J. C. Barats
1Onco-Hematology Unit, University Hospitals of Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Medical Oncology Unit, University Hospitals of Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Gynecology and Obstetrics I Unit, University Hospitals of Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Onco-Hematology Unit, Center Hospital of Colmar, Colmar, France; Oncology and Radiotherapy Unit, Hasenrain Hospital, Mulhouse, France; Gynecological and Obstetrical Unit, Center Medico-Chirurgical and Obstétrical, Schiltigheim, France; Maternity, University Hospitals of Strasbourg, Strasbourg, France.
Abstract:
Prognosis of ovarian carcinoma in complete histologic remission (CHR) at second-look surgery is still controversial. In a series of 83 patients in CHR we studied retrospectively several prognostic factors (age, stage, histologic grade, histologic type, initial residual disease after surgery, CA 125 normalization period) to determine which patients present a high risk of relapsing after CHR and could be included in therapeutic protocols for consolidation treatment. Univariate analysis showed that the combination of CA 125 normalization < 8 weeks with absence of macroscopic tumoral residue after initial surgery permits the definition of a group with a very good prognosis, while for patients with CA 125 normalization period > 8 weeks and an initial macroscopic residual tumor, the prognosis is relatively poor (progression-free survival 100% vs. 47%, at 2 years P < 0.05). Using the Cox multivariate analysis, only the initial tumoral residue is of prognostic significance for progression-free survival; there is no prognostic significance for overall survival. The therapeutic strategy for ovarian cancer may be improved for patients in CHR after second-look surgery by determining those at high risk, making it possible to confine consolidation treatment trials to such a group.